Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

9.27
-0.2000-2.11%
Post-market: 9.270.00000.00%16:10 EDT
Volume:128.65K
Turnover:1.19M
Market Cap:129.84M
PE:-1.36
High:9.74
Open:9.59
Low:9.12
Close:9.47
52wk High:17.40
52wk Low:4.86
Shares:14.01M
Float Shares:11.66M
Volume Ratio:0.63
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.02
PE(LYR):-0.75

Loading ...

Kazia Says Sovargen Doses First Patient in Phase 1b/2a Paxalisib Trial for Rare Seizure Disorders, Triggers $2 Million Payment

Reuters
·
Sep 22

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1B/2a Trial of Paxalisib for Rare Seizure Disorders

THOMSON REUTERS
·
Sep 22

Kazia Therapeutics Switches ADR Depositary to JPMorgan; NASDAQ-Listed ADSs Stay Under KZIA

Reuters
·
Sep 19

Kazia Therapeutics Doses First Patient in Pnoc035 Phase 2 Paxalisib-Gemcitabine Trial for Recurrent Pediatric AT/RT

Reuters
·
Sep 09

Kazia Therapeutics Announces First Patient Dosed in Pnoc035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric at/Rt Brain Cancer

THOMSON REUTERS
·
Sep 09

Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study

MT Newswires Live
·
Sep 01

Kazia Therapeutics - Paxalisib Monotherapy Reduced Tumor Burden; Addition of Pembrolizumab Drove Further Reduction

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics - Phase 2 Trial Enrollment Expected to Begin Q1 2027, Full Enrollment by End of 2027

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics - Plans Five-Arm Phase 2 Trial of Paxalisib Monotherapy and Combination with Pembrolizumab

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant Mss/Pmmr Colorectal Cancer and Enhances Response to Immunotherapy

THOMSON REUTERS
·
Sep 01

Kazia Expands Paxalisib Trial into Hr+/her2- Advanced Breast Cancer

Reuters
·
Sep 01

Kazia Therapeutics Expands Paxalisib Clinical Trial into Hr+/Her2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in Hr+ Breast Cancer

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics - Clinical Updates Expected Throughout 2027, Full Readout Anticipated in 2028

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics Limited Announces Oversubscribed Closing of up to $120 Million Public Offering

THOMSON REUTERS
·
Sep 01

Kazia Therapeutics - Files for Offering of 95,110 American Depositary Shares Representing 47,555,000 Ordinary Shares - SEC Filing

THOMSON REUTERS
·
Aug 31

Kazia Therapeutics Launches Registered Public Offering of ADSs and Warrants

Reuters
·
Aug 31

U.S. Stocks on the MOVE-Halliburton, BioNTech, Kazia Therapeutics

Reuters
·
Aug 29

Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Kazia Therapeutics (KZIA) and Cerus (CERS)

TIPRANKS
·
Aug 28

Kazia Therapeutics Limited Announces Pricing of up to $120 Million Public Offering

THOMSON REUTERS
·
Aug 28

Kazia Therapeutics Ltd: Files to Offer up to $80 Mln of American Depositary Shares Representing Ordinary Shares- SEC Filing

THOMSON REUTERS
·
Aug 28